HAPPENING NOW
New T-cell engager shows promise for advanced solid tumors
As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first…
As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors. IMA401 is a so-called bispecific T-cell engager (TCER) that specifically links cancer cells with T cells, thereby directly activating the immune system to fight the tumor. To a…
Read full article on MedicalxpressAI summaries can be wrong sometimes—always verify important details using the source article.
Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.
Support HappeningNow